Starpharma receives $4.9M R&D tax incentive refund
Filed with ASX · · 2 pages · English
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- DEP cabazitaxel progresses to phase 2 on positive results
- AGM - Chairman address and CEO presentation
- VivaGel condom receives regulatory approval in Europe
- UK launch of VivaGel BV
- DEP outperforms Gemzar in human pancreatic cancer model
Later from Starpharma
- Commencement of phase 1 trial for AZD0466 utilising DEP
- Quarterly Cashflow Report
- Starpharma receives US$3M milestone from AstraZeneca
- VivaGel BV launched in Asia
- Okamoto licenses VivaGel antiviral condom in Asian countries
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma